WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: XLO), a clinical-stage biotechnology company discovering and ...

Recent research has shown that certain forms of E. coli bacteria tend to colonize hypoxic areas of the body, including tumors, suggesting they might be playing a role in cancer therapeutics.

Researchers at the Spanish National Cancer Research Center (CNIO) propose a new treatment for brain metastases that respond ...

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class ...

A Cleveland Clinic-led research collaboration between Timothy Chan, MD, Ph.D., Chair of Cleveland Clinic's Global Center for ...

In a follow-up study, researchers compared cancer immunotherapy in mice, using either single or double immune responses. And ...

Thanks to early detection through widespread screening and dramatic breakthroughs in immunotherapy and other cancer ...

Title: NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naive MSS/MSI-L colorectal cancer (CRC) Lead Author: ...

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) ...

North America Cancer Immunotherapy Market is expanding rapidly due to expanding approval of immunotherapeutic drugs for the treatment of increasing incidences of cancer and increasing investments in ...

Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its ...